{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:17:45Z","timestamp":1791919065964,"version":"4.3.4"},"reference-count":195,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Natural killer (NK) cells are cellular components of the innate immune system that can recognize and suppress the proliferation of cancer cells. NK cells can eliminate cancer cells through direct lysis, by secreting perforin and granzymes, or through antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC involves the binding of the Fc gamma receptor IIIa (CD16), present on NK cells, to the constant region of an antibody already bound to cancer cells. Cancer cells use several mechanisms to evade antitumor activity of NK cells, including the accumulation of inhibitory cytokines, recruitment and expansion of immune suppressor cells such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), modulation of ligands for NK cells receptors. Several strategies have been developed to enhance the antitumor activity of NK cells with the goal of overcoming cancer cells resistance to NK cells. The three main strategies to engineer and boost NK cells cytotoxicity include boosting NK cells with modulatory cytokines, adoptive NK cell therapy, and the employment of engineered NK cells to enhance antibody-based immunotherapy. Although the first two strategies improved the efficacy of NK cell-based therapy, there are still some limitations, including immune-related adverse events, induction of immune-suppressive cells and further cancer resistance to NK cell killing. One strategy to overcome these issues is the combination of monoclonal antibodies (mAbs) that mediate ADCC and engineered NK cells with potentiated anti-cancer activity. The advantage of using mAbs with ADCC activity is that they can activate NK cells, but also favor the accumulation of immune effector cells to the tumor microenvironment (TME). Several clinical trials reported that combining engineered NK cells with mAbs with ADCC activity can result in a superior clinical response compared to mAbs alone. Next generation of clinical trials, employing engineered NK cells with mAbs with higher affinity for CD16 expressed on NK cells, will provide more effective and higher-quality treatments to cancer patients.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1275904","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T05:08:46Z","timestamp":1700802526000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Massimo","family":"Fantini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip Martin","family":"Arlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwong Yok","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1007\/s00018-016-2210-5","article-title":"Effects of radiation on metastasis and tumor cell migration","volume":"73","author":"Vilalta","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41598-023-28309-5","article-title":"An evaluation of the Index4 tool for chemotherapy toxicity prediction in cancer patients older than 70 years old","volume":"13","author":"Lewis","year":"2023","journal-title":"Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-med-112311-083918","article-title":"Harnessing the power of the immune system to target cancer","volume":"64","author":"Liz\u00e9e","year":"2013","journal-title":"Annu Rev Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases\u2013elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/s0098-2997(00)00007-8","article-title":"The molecular biology of cancer","volume":"21","author":"Bertram","year":"2000","journal-title":"Mol Aspects Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-013-0645-9","article-title":"Immune system: a double-edged sword in cancer","volume":"62","author":"Lakshmi Narendra","year":"2013","journal-title":"Inflammation Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130960","article-title":"T cell regulation of natural killer cells","volume":"210","author":"Kerdiles","year":"2013","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev.immunol.021908.132544","article-title":"Immune therapy for cancer","volume":"27","author":"Dougan","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0301-472x(01)00696-8","article-title":"The biology of natural killer cells in cancer, infection, and pregnancy","volume":"29","author":"Miller","year":"2001","journal-title":"Exp Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/172460080702200208","article-title":"Involvement of NK cells against tumors and parasites","volume":"22","author":"Papazahariadou","year":"2007","journal-title":"Int J Biol Markers"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2013.10","article-title":"NK cell-based immunotherapy for Malignant diseases","volume":"10","author":"Cheng","year":"2013","journal-title":"Cell Mol Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00661","article-title":"NKG2D\/NKG2-ligand pathway offers new opportunities in cancer treatment","volume":"10","author":"Frazao","year":"2019","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00476","article-title":"NKG2D and its ligands: \"One for all, all for one\"","volume":"9","author":"Zingoni","year":"2018","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","article-title":"Cancer immunoediting from immune surveillance to immune escape","volume":"121","author":"Kim","year":"2007","journal-title":"Immunology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/B978-0-12-800267-4.00003-1","article-title":"Recognition of tumors by the innate immune system and natural killer cells","volume":"122","author":"Marcus","year":"2014","journal-title":"Adv Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181454","article-title":"NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing","volume":"216","author":"Prager","year":"2019","journal-title":"J Exp Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.MR0718-269R","article-title":"Mechanisms of natural killer cell-mediated cellular cytotoxicity","volume":"105","author":"Prager","year":"2019","journal-title":"J Leukoc Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00076","article-title":"Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies","volume":"4","author":"Seidel","year":"2013","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00490","article-title":"The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity","volume":"4","author":"Baginska","year":"2013","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.1.240","article-title":"Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1","volume":"182","author":"Li","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.633205","article-title":"Natural killer cell interactions with myeloid derived suppressor cells in the tumor microenvironment and implications for cancer immunotherapy","volume":"12","author":"Zalfa","year":"2021","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0785","article-title":"Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness","volume":"70","author":"Giannoni","year":"2010","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00122","article-title":"Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity","volume":"5","author":"Chretien","year":"2014","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.6.2803","article-title":"CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity","volume":"168","author":"Markel","year":"2002","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.11.6692","article-title":"Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1","volume":"174","author":"Stern","year":"2005","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.2MR1218-501R","article-title":"Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy","volume":"105","author":"Wu","year":"2019","journal-title":"J Leukoc Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0123","article-title":"Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis","volume":"73","author":"Bramswig","year":"2013","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21382","article-title":"Soluble MICA in Malignant diseases","volume":"118","author":"Holdenrieder","year":"2006","journal-title":"Int J Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2019.1017","article-title":"Tumor-derived soluble MICA obstructs the NKG2D pathway to restrain NK cytotoxicity","volume":"11","author":"Luo","year":"2020","journal-title":"Aging Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1593\/neo.04316","article-title":"Downregulation and\/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma","volume":"6","author":"Raffaghello","year":"2004","journal-title":"Neoplasia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.012.10025","article-title":"Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma","volume":"32","author":"Li","year":"2013","journal-title":"Chin J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2013.14.10.5651","article-title":"Clinical significance of soluble major histocompatibility complex class I chain-related in a renal cell carcinoma patients","volume":"14","author":"Qiu","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"B41","article-title":"Prognostic significance of serum sMICA levels in non-small cell lung cancer","volume":"19","author":"Wang","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00926","article-title":"MICA-129 dimorphism and soluble MICA are associated with the progression of multiple myeloma","volume":"9","author":"Zingoni","year":"2018","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/mc.22667","article-title":"Soluble MICA is elevated in pancreatic cancer: Results from a population based case-control study","volume":"56","author":"Onyeaghala","year":"2017","journal-title":"Mol Carcinog"},{"key":"B44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13046-023-02649-6","article-title":"First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors","volume":"42","author":"Cole","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/205796","article-title":"Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer","volume":"2014","author":"Romee","year":"2014","journal-title":"Scientifica (Cairo)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03013","article-title":"Exploiting human NK cells in tumor therapy","volume":"10","author":"Vacca","year":"2020","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0195","article-title":"IL2 variant circumvents ICOS+ Regulatory T-cell expansion and promotes NK cell activation","volume":"4","author":"Sim","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3603","article-title":"Molecular pathways: interleukin-15 signaling in health and in cancer","volume":"20","author":"Mishra","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood.v97.1.14","article-title":"Interleukin 15: biology and relevance to human disease","volume":"97","author":"Fehniger","year":"2001","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-311456","article-title":"Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques","volume":"117","author":"Waldmann","year":"2011","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1172\/JCI90387","article-title":"CD56bright NK cells exhibit potent antitumor responses following IL-15 priming","volume":"127","author":"Wagner","year":"2017","journal-title":"J Clin Invest"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123586","article-title":"Immunomodulatory effects of IL-2 and IL-15; implications for cancer immunotherapy","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.9.6072","article-title":"Combined IL-15\/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo","volume":"177","author":"Stoklasek","year":"2006","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","article-title":"Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models","volume":"4","author":"Rhode","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2018.2628","article-title":"An IL-15 superagonist, ALT-803, enhances antibody-dependent cell-mediated cytotoxicity elicited by the monoclonal antibody NEO-201 against human carcinoma cells","volume":"34","author":"Fantini","year":"2019","journal-title":"Cancer Biother Radiopharm"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomized, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.06.001","article-title":"Bifunctional TGF-\u03b2 trap\/IL-15 protein complex elicits potent NK cell and CD8+ T cell immunity against solid tumors","volume":"29","author":"Liu","year":"2021","journal-title":"Mol Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.01.025","article-title":"Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells","volume":"30","author":"Chaturvedi","year":"2022","journal-title":"Mol Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J Exp Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1523-1","article-title":"Interleukin 12: still a promising candidate for tumor immunotherapy","volume":"63","author":"Lasek","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumors","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1434-6","article-title":"Immune-suppressive properties of the tumor microenvironment","volume":"62","author":"Becker","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B67","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/1078-0432.CCR-18-1512","article-title":"First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors","volume":"25","author":"Strauss","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2021.1880717","article-title":"Interleukin-18 promotes the antitumor ability of natural killer cells in colorectal cancer via the miR-574-3p\/TGF-\u03b21 axis","volume":"12","author":"Li","year":"2021","journal-title":"Bioengineered"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1655","article-title":"Augmentation of immune checkpoint cancer immunotherapy with IL18","volume":"22","author":"Ma","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24100","article-title":"A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma","volume":"115","author":"Tarhini","year":"2009","journal-title":"Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3379","article-title":"Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells","volume":"72","author":"Terme","year":"2012","journal-title":"Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16281","article-title":"Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-499707","article-title":"Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation","volume":"124","author":"Zhu","year":"2014","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324533","article-title":"IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors","volume":"33","author":"Sivori","year":"2003","journal-title":"Eur J Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605502","article-title":"Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with esophageal squamous cell carcinoma","volume":"102","author":"Watanabe","year":"2010","journal-title":"Br J Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/696578","article-title":"IL-21: a pleiotropic cytokine with potential applications in oncology","volume":"2015","author":"Croce","year":"2015","journal-title":"J Immunol Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704086","article-title":"IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I\/II trial","volume":"32","author":"Burns","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0683","article-title":"Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial","volume":"10","author":"Krause","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12967-015-0632-8","article-title":"Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer","volume":"13","author":"Sakamoto","year":"2015","journal-title":"J Transl Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28020105","article-title":"The advances and challenges of NK cell-based cancer immunotherapy","volume":"28","author":"Kang","year":"2021","journal-title":"Curr Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current perspectives on \"Off-the-shelf\" Allogeneic NK and CAR-NK cell therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14564","article-title":"Clinical-scale production of cGMP compliant CD3\/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution","volume":"58","author":"Williams","year":"2018","journal-title":"Transfusion"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167666","article-title":"The application of autologous cancer immunotherapies in the age of memory-NK cells","volume":"14","author":"Lizana-Vasquez","year":"2023","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1038\/s41467-020-19094-0","article-title":"Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells","volume":"11","author":"Mark","year":"2020","journal-title":"Nat Commun"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/s0301-472x(00)00617-2","article-title":"Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood","volume":"29","author":"Condiotti","year":"2001","journal-title":"Exp Hematol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584099","article-title":"Cord-blood natural killer cell-based immunotherapy for cancer","volume":"11","author":"Zhao","year":"2020","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2011.12.015","article-title":"The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation","volume":"73","author":"Luevano","year":"2012","journal-title":"Hum Immunol"},{"key":"B89","article-title":"High expression of NKG2A\/CD94 and low expression of granzyme B are associated with reduced cord blood NK cell activity","volume":"4","author":"Wang","year":"2007","journal-title":"Cell Mol Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07768.x","article-title":"The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells","volume":"147","author":"Verneris","year":"2009","journal-title":"Br J Haematol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9728-2_12","article-title":"An improved method to produce clinical-scale natural killer cells from human pluripotent stem cells","volume":"2048","author":"Zhu","year":"2019","journal-title":"Methods Mol Biol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-165225","article-title":"Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity","volume":"113","author":"Woll","year":"2009","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.841107","article-title":"iPSC-derived natural killer cell therapies - expansion and targeting","volume":"13","author":"Goldenson","year":"2022","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1089\/15258160152509145","article-title":"Cellular immunotherapy of Malignancies using the clonal natural killer cell line NK-92","volume":"10","author":"Tonn","year":"2001","journal-title":"J Hematother Stem Cell Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.12.003","article-title":"The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer","volume":"25","author":"Klingemann","year":"2023","journal-title":"Cytotherapy"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19204","article-title":"A phase I trial of NK-92 cells for refractory hematological Malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy","volume":"8","author":"Williams","year":"2017","journal-title":"Oncotarget"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.02.008","article-title":"A phase I study to determine the maximum tolerated dose of ex vivo expanded natural killer cells derived from unrelated, HLA-disparate adult donors","volume":"28","author":"Otegbeye","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0118","article-title":"Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with Malignant lymphoma or advanced solid tumors","volume":"4","author":"Yang","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.953175","article-title":"Editorial: engineered targeted cancer immunotherapies","volume":"12","author":"Fantini","year":"2022","journal-title":"Front Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744823","article-title":"Advances in universal CAR-T cell therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3390\/cells12121606","article-title":"Recent advances in CAR-based solid tumor immunotherapy","volume":"12","author":"Shin","year":"2023","journal-title":"Cells"},{"key":"B104","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01435-3","article-title":"CAR-NK cell therapy for hematological Malignancies: recent updates from ASH 2022","volume":"16","author":"Huang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010117","article-title":"CAR-NK as a rapidly developed and efficient immunotherapeutic strategy against cancer","volume":"15","author":"W\u0142odarczyk","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953849","article-title":"Overcoming tumor resistance mechanisms in CAR-NK cell therapy","volume":"13","author":"Valeri","year":"2022","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40164-022-00341-7","article-title":"Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential","volume":"11","author":"Wang","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1999.1505","article-title":"Paul Ehrlich's passion: the origins of his receptor immunology","volume":"194","author":"Silverstein","year":"1999","journal-title":"Cell Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1078-0432.CCR-09-2345","article-title":"Immunotherapy of Malignant disease with tumor antigen-specific monoclonal antibodies","volume":"16","author":"Campoli","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0028","article-title":"What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"14","author":"Robert","year":"2009","journal-title":"Oncologist"},{"key":"B113","article-title":"Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer","volume":"11","author":"Kline","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.1041","article-title":"Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab","volume":"33","author":"McDermott","year":"2015","journal-title":"J Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (Anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.06.008","article-title":"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","volume":"33","author":"Andr\u00e9","year":"2022","journal-title":"Ann Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-4162","article-title":"Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from checkMate 275","volume":"26","author":"Galsky","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jtho.2019.01.016","article-title":"Health-related quality of life in KEYNOTE-010: a phase II\/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC","volume":"14","author":"Barlesi","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02152","article-title":"Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309\/KEYNOTE-775","volume":"41","author":"Makker","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J Clin Oncol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J Clin Oncol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/bju.15058","article-title":"Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma","volume":"126","author":"Pal","year":"2020","journal-title":"BJU Int"},{"key":"B130","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eururo.2021.03.024","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma: A long-term overall survival and safety update from the phase 3 IMvigor211 clinical trial","volume":"80","author":"van der Heijden","year":"2021","journal-title":"Eur Urol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicenter, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.2174\/1389450124666230330101651","article-title":"The clinical safety and efficacy of targeted PD-L1 therapy with durvalumab in solid tumors","volume":"24","author":"Chen","year":"2023","journal-title":"Curr Drug Targets"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00481","article-title":"Targeting the antibody checkpoints to enhance cancer immunotherapy-focus on fc\u03b3RIIB","volume":"10","author":"Teige","year":"2019","journal-title":"Front Immunol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22690","article-title":"Regulation of PD-1\/PD-L1 pathway and resistance to PD-1\/PD-L1 blockade","volume":"8","author":"Bai","year":"2017","journal-title":"Oncotarget"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2005.08.004","article-title":"Flow cytometric assay for determination of FcgammaRIIIA-158 V\/F polymorphism","volume":"306","author":"B\u00f6ttcher","year":"2005","journal-title":"J\u00a0Immunol Methods"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/12.suppl_1.s81","article-title":"Targeting HER2 in other tumor types","author":"Scholl","year":"2001","journal-title":"Ann Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/S1086-5802(16)30498-3","article-title":"First MAb approved for treatment of metastatic breast cancer","volume":"39","author":"Brenner","year":"1999","journal-title":"J Am Pharm Assoc (Wash)"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0b013e31822c3a0f","article-title":"HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge","volume":"19","author":"Hicks","year":"2011","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2068","article-title":"Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2","volume":"67","author":"Varchetta","year":"2007","journal-title":"Cancer Res"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8957","article-title":"Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu-positive metastatic breast cancer","volume":"26","author":"Musolino","year":"2008","journal-title":"J Clin Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq585","article-title":"Fc\u03b3R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer","volume":"22","author":"Tamura","year":"2011","journal-title":"Ann Oncol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199811000-00012","article-title":"Use of rituximab, the new FDA-approved antibody","volume":"10","author":"Leget","year":"1998","journal-title":"Curr Opin Oncol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363080-00005","article-title":"Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"key":"B148","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1634\/theoncologist.2010-0306","article-title":"U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia","volume":"16","author":"Casak","year":"2011","journal-title":"Oncologist"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1945031","article-title":"Ibrutinib plus rituximab for the treatment of adult patients with Waldenstr\u00f6m's macroglobulinemia: a safety evaluation","volume":"20","author":"Migkou","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-351411","article-title":"Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism","volume":"118","author":"Veeramani","year":"2011","journal-title":"Blood"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-009480","article-title":"FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma","volume":"108","author":"Kim","year":"2006","journal-title":"Blood"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.059","article-title":"Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstr\u00f6m's macroglobulinemia","volume":"23","author":"Treon","year":"2005","journal-title":"J Clin Oncol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1728","article-title":"Cetuximab","author":"Goldberg","year":"2005","journal-title":"Nat Rev Drug Discovery"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0458","article-title":"Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer","volume":"18","author":"Cohen","year":"2013","journal-title":"Oncologist"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1960-8","article-title":"Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favorable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy","volume":"66","author":"Lattanzio","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.0463","article-title":"Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan","volume":"27","author":"Bibeau","year":"2009","journal-title":"J Clin Oncol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0184","article-title":"Prospective evaluation of cetuximab-mediated antibody-dependent cell cytotoxicity in metastatic colorectal cancer patients predicts treatment efficacy","volume":"4","author":"Trotta","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B160","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00262-008-0613-3","article-title":"FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck","volume":"58","author":"Taylor","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0697-4","article-title":"Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells","volume":"58","author":"L\u00f3pez-Albaitero","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells","volume":"3","author":"Boyerinas","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1466018","article-title":"Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types","volume":"7","author":"Hicks","year":"2018","journal-title":"Oncoimmunology"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02140","article-title":"Avelumab, an igG1 anti-PD-L1 immune checkpoint inhibitor, triggers NK cell-mediated cytotoxicity and cytokine production against triple negative breast cancer cells","volume":"9","author":"Juli\u00e1","year":"2018","journal-title":"Front Immunol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0749-6","article-title":"Avelumab: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1448271","article-title":"Avelumab for the treatment of urothelial cancer","volume":"18","author":"Rodriguez-Vida","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"B167","article-title":"The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update","volume":"29","author":"Gurram","year":"2020","journal-title":"Discovery Med"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"B170","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13046-022-02332-2","article-title":"Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial","volume":"41","author":"Della Corte","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5135","article-title":"HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity","volume":"6","author":"Peipp","year":"2015","journal-title":"Oncotarget"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2021-0229","article-title":"Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen","volume":"403","author":"Kellner","year":"2021","journal-title":"Biol Chem"},{"key":"B173","doi-asserted-by":"publisher","first-page":"e1058459","DOI":"10.1080\/2162402X.2015.1058459","article-title":"Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30","volume":"5","author":"Kellner","year":"2015","journal-title":"Oncoimmunology"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31285","article-title":"Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer","volume":"142","author":"Ishikawa","year":"2018","journal-title":"Int J Cancer"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0768","article-title":"Phase I trial of expanded, activated autologous NK-cell infusions with trastuzumab in patients with HER2-positive cancers","volume":"26","author":"Lee","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.226696","article-title":"Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive Malignant lymphoma patients","volume":"105","author":"Tanaka","year":"2020","journal-title":"Haematologica"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.12.025","article-title":"Phase I study: safety and efficacy of an ex vivo-expanded allogeneic natural killer cell (MG4101) with rituximab for relapsed\/refractory B cell non-hodgkin lymphoma","volume":"29","author":"Yoon","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade3341","article-title":"Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma","volume":"15","author":"Cichocki","year":"2023","journal-title":"Sci Transl Med"},{"key":"B179","article-title":"Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC)","volume":"8","author":"Liang","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03158-9","article-title":"Phase I study of expanded natural killer cells in combination with cetuximab for recurrent\/metastatic nasopharyngeal carcinoma","volume":"71","author":"Lim","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13411","article-title":"An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele","volume":"7","author":"Jochems","year":"2016","journal-title":"Oncotarget"},{"key":"B182","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.oraloncology.2019.01.017","article-title":"Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells","volume":"90","author":"Friedman","year":"2019","journal-title":"Oral Oncol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30767","article-title":"ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody","volume":"141","author":"Jochems","year":"2017","journal-title":"Int J Cancer"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1007\/s10616-021-00476-1","article-title":"An NK cell line (NK92-41BB) expressing high levels of granzyme is engineered to express the high affinity chimeric genes CD16\/CAR","volume":"73","author":"Zhao","year":"2021","journal-title":"Cytotechnology"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112724","article-title":"A novel off-the-shelf trastuzumab-armed NK cell therapy (ACE1702) using antibody-cell-conjugation technology","volume":"13","author":"Li","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1424673","article-title":"In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial","volume":"7","author":"Adotevi","year":"2018","journal-title":"Oncoimmunology"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00105","article-title":"Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19","volume":"7","author":"Carlsten","year":"2016","journal-title":"Front Immunol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.737311","article-title":"The right partner in crime: unlocking the potential of the anti-EGFR antibody cetuximab via combination with natural killer cell chartering immunotherapeutic strategies","volume":"12","author":"Baysal","year":"2021","journal-title":"Front Immunol"},{"key":"B189","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40265-021-01485-2","article-title":"Margetuximab: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S165615","article-title":"Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma","volume":"12","author":"Ollila","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0084","article-title":"Obinutuzumab for the treatment of indolent lymphoma","volume":"12","author":"Edelmann","year":"2016","journal-title":"Future Oncol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211073575","article-title":"Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma","volume":"28","author":"Davis","year":"2022","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03306-1","article-title":"\u03b1VEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade","volume":"72","author":"Pan","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2256904","article-title":"Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer","volume":"19","author":"Huan","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2023.03.018","article-title":"Process engineering of natural killer cell-based immunotherapy","volume":"41","author":"Motallebnejad","year":"2023","journal-title":"Trends Biotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1275904\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T05:08:54Z","timestamp":1700802534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1275904\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":195,"alternative-id":["10.3389\/fimmu.2023.1275904"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1275904","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]},"article-number":"1275904"}}